Axovant Sciences Ltd. Common Sh (AXON) 15.28

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Axovant Sciences Ltd. Common Sh (AXON) 15.28 $AXON

Doctors Say Yearly Memory Evaluations are Critical to Early Diagnosis, Effective Treatment of Alzheimer's Disease
PR Newswire - Wed Sep 21, 7:00AM CDT
Memory evaluations are critical to the early diagnosis and effective treatment of people with Alzheimer's disease, according to Dr. Gary Small, director of geriatric psychiatry at UCLA's Semel Institute for Neuroscience and Human Behavior.
AXON: 15.28 (+0.14)

Axovant Sciences to Present at the Morgan Stanley Global Healthcare Conference
PR Newswire - Tue Sep 06, 3:30PM CDT
Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that the company will be presenting at the Morgan Stanley Global Healthcare Conference on September 13 at 5:15 p.m. EDT.
AXON: 15.28 (+0.14), MS: 31.91 (-0.33)

Axovant Sciences to Present at the Baird 2016 Global Healthcare Conference
PR Newswire - Wed Aug 31, 3:30PM CDT
Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that the company will be presenting at the Baird 2016 Global Healthcare Conference on September 7 at 10:50 a.m. EDT.
AXON: 15.28 (+0.14)

Karuna Pharmaceuticals Appoints Atul Pande, M.D., to Board of Directors
BusinessWire - Fri Jul 29, 9:00AM CDT
Karuna Pharmaceuticals, a company focused on targeting muscarinic receptors for the treatment of central nervous system disorders, today announced the appointment of Atul Pande, M.D., to its Board of Directors. Dr. Pande brings to Karuna more than 25 years of experience in the fields of psychiatry and neurosciences and an expertise in drug development.
AXON: 15.28 (+0.14), GSK: 43.42 (-0.16)

Axovant Sciences Announces 2015 Fiscal Year-End Financial Results and Corporate Updates
PR Newswire - Mon Jun 06, 7:00AM CDT
Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today reported financial results for the fourth fiscal quarter and twelve months ended March 31, 2016.
AXON: 15.28 (+0.14)

Global Lewy Body Dementia Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Axovant Sciences, BioArctic Neuroscience, Immungenetics - Research and Markets
BusinessWire - Mon May 16, 10:43AM CDT
Research and Markets has announced the addition of the "Lewy body Dementia - Pipeline Review, H1 2016" report to their offering.
AXON: 15.28 (+0.14)

Merck KGaA (MKGAF) Q1 Earnings: What Awaits the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:38AM CDT
Merck KGaA (MKGAF) is scheduled to report its first-quarter 2016 earnings results on May 19.
AXON: 15.28 (+0.14), BMRN: 97.40 (-0.05), PFE: 34.26 (+0.11)

Should You Buy Axovant Sciences (AXON) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:35AM CDT
Axovant Sciences (AXON) looks poised to beat analyst estimates this earnings season, with a favourable Zacks Rank and an ESP in positive territory.
AXON: 15.28 (+0.14)

Drug Stocks Reporting Earnings on May 17: AXON & FWP
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:31AM CDT
Quite a few beats and some misses. That's how the first-quarter scorecard cycle looks like as the earnings season nears its end for 10 of the 16 Zacks sectors.
AXON: 15.28 (+0.14), ABT: 42.19 (-0.03), JNJ: 118.81 (-0.65), FWP: 20.21 (+0.26), PFE: 34.26 (+0.11), AMGN: 174.80 (-0.82), ABBV: 64.98 (-0.10), NVS: 81.48 (-0.55)

Axovant Sciences Appoints Dr. Gary P. Pisano to Board of Directors
PR Newswire - Fri May 13, 5:59AM CDT
Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced Gary P. Pisano has joined its Board of Directors and will also serve as a member of the Board's Audit Committee. Gary Pisano is the Harry E. Figgie Professor of Business Administration at the Harvard Business School and has been on the Harvard faculty since 1988. His work has focused on a wide range of topics including pharmaceutical research and development processes.
AXON: 15.28 (+0.14)

Axovant Sciences to Present at Upcoming Investor Conferences
PR Newswire - Mon May 09, 3:00PM CDT
Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced upcoming presentations at two investor conferences:
AXON: 15.28 (+0.14)

Leigh Steinberg Joins Retired NFL Players in Highlighting Need for Greater Participation in Alzheimer's Clinical Trials
PR Newswire - Tue Apr 26, 6:30AM CDT
Leigh Steinberg, the legendary sports agent and inspiration for the film "Jerry Maguire," is joining retired NFL players in calling attention to the need for greater participation in Alzheimer's clinical trials.
AXON: 15.28 (+0.14)

Call to Action for Participation in Clinical Trials is Topic of Symposium at Alzheimer's Disease International Conference 2016
PR Newswire - Tue Apr 19, 6:30AM CDT
Axovant Sciences Ltd. (NYSE: AXON) today announced it is sponsoring a symposium at the Alzheimer's Disease International Conference 2016: "Alzheimer's Community Call to Action: Developing New Treatments Through Clinical Trial Participation."
AXON: 15.28 (+0.14)

Retired NFL Players Call for Greater Participation in Alzheimer's Clinical Trials as Ambassadors at Educational Events, Memory Screenings in U.S., Canada
PR Newswire - Mon Apr 18, 6:30AM CDT
"Huddle Up for New Alzheimer's Treatments" Campaign Adds Joe Rose, Joey Harrington, Ron Pitts, Christian Fauria, Steve Tasker to Line-Up with Solomon Wilcots
AXON: 15.28 (+0.14)

Axovant reports 3Q loss
Automated Insights - Tue Feb 09, 5:36PM CST
HAMILTON, Bermuda (AP) _ Axovant Sciences Ltd. (AXON) on Tuesday reported a loss of $63.4 million in its fiscal third quarter.
AXON: 15.28 (+0.14)

Axovant Sciences Announces Launch of First-in-Class Clinical Programs for Lewy Body Dementia and Reports Financial Results for the Third Fiscal Quarter Ended December 31, 2015
PR Newswire - Tue Feb 09, 3:15PM CST
Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced further details of three new clinical trials to address cognitive, behavioral and functional aspects of Lewy body dementia, a disease affecting approximately 1.4 million people in the U.S. Two out of the three studies were recently initiated and the third is expected to start later this quarter. In addition, the Company reported financial results for the third fiscal quarter and nine months ended December 31, 2015.
AXON: 15.28 (+0.14)

Alzheimer's Disease - Pipeline Review, H2 2015
M2 - Mon Feb 08, 11:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/xwvj4d/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Alzheimer's Disease Overview - Therapeutics Development - Pipeline Products for Alzheimer's Disease - Overview - Pipeline Products for Alzheimer's Disease - Comparative Analysis - Alzheimer's Disease - Therapeutics under Development by Companies - Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes - Alzheimer's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Alzheimer's Disease - Products under Development by Companies - Alzheimer's Disease - Products under Investigation by Universities/Institutes - Alzheimer's Disease - Companies Involved in Therapeutics Development(Partial List) - AB Science SA - AbbVie Inc. - AC Immune SA - Acelot, Inc. - Actinogen Limited - Acumen Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Aequus Pharmaceuticals Inc. - AFFiRiS AG - Alector LLC - Alkermes Plc - ALSP, Inc. - Alzhyme Pty Ltd - Alzinova AB - AlzProtect SAS - Amarantus Bioscience Holdings, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - Aphios Corporation - Apodemus AB - Applied Research using OMIC Sciences, S.L. - Araclon Biotech, S.L. - Archer Pharmaceuticals, Inc. - ArmaGen,Inc. - Artery Therapeutics, Inc. - AskAt Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Asubio Pharma Co., Ltd. - Ausio Pharmaceuticals, LLC - Avergen Ltd - Avineuro Pharmaceuticals, Inc. - Axerion Therapeutics, Inc. - Axon Neuroscience SE - Axovant Sciences Ltd. For more information visit http://www.researchandmarkets.com/research/xwvj4d/alzheimers
AXON: 15.28 (+0.14), AVXL: 3.11 (-0.17), AZN: 33.97 (-0.31), AMGN: 174.80 (-0.82), ABBV: 64.98 (-0.10), ALKS: 49.58 (-1.42)

Biotech Stock Roundup: Biogen, Amgen Top Estimates; Zika Virus Grabs Attention
Arpita Dutt - Zacks Investment Research - Wed Feb 03, 7:28AM CST
It was all about earnings last week though growing concerns regarding the spread of the Zika virus put some companies in the spotlight.
AXON: 15.28 (+0.14), BIIB: 312.58 (-2.23), INCY: 88.98 (-0.29), NLNK: 12.87 (+0.86), XON: 27.41 (-0.63), ABBV: 64.98 (-0.10), REGN: 410.39 (+2.38)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Colon Cleanse Advice Deserves a Careful Read First

Updated Category News Views 93

Wellness copy can sound harmless right up until it blurs comfort guidance with health guidance. HelloNation’s feature on what to expect after a colon cleanse, drawing on Suzanne Childre of Gentle Wellness Center in Santa Monica, lays out a fairly familiar recovery script: drink water, rest, eat lightly, expect some bowel changes, and do not panic over a little fatigue....

Continue Reading
Refund Delays Are Becoming an E-Commerce Sales Risk

Updated Category News Views 176

A returned jacket can turn into a household cash-flow problem faster than retailers seem willing to admit. Seel's new survey lands at an awkward moment for online merchants: shoppers are not merely annoyed by slow refunds; many are budgeting around them. Among 1,921 U.S. adults who had shopped online in the prior six months, 63% said waiting for a retailer to receive a...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 130

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 51

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading
Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 45

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
CATL Builds Türkiye Battery Service Muscle in Istanbul

Updated Category News Views 43

Battery warranties look mighty impressive until a pack needs work on a Tuesday morning and nobody nearby can touch it. CATL's new NING SERVICE Experience Center in Istanbul goes straight at that unglamorous problem. The facility, announced November 19, 2026, is described as Türkiye's first dedicated battery depot repair center and an integrated sales-and-service hub. It...

Continue Reading
Compounded Peptides Demand Clearer FDA Status Answers

Updated Category News Views 73

Peptide talk has gotten muddled enough to make plain English feel revolutionary. The central point in the HelloNation article featuring wellness expert Andres Giraldo is straightforward: a compounded peptide is not FDA approved in the same product-specific manner as a commercially manufactured drug. That is not a small semantic wrinkle, and it should not be buried beneath...

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 148

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
IT Tech Packaging's Going-Concern Warning Lands Hard

Updated Category News Views 76

A paper maker can survive plenty of ugly quarters; it cannot casually shrug off an auditor questioning whether it can keep operating. That is the cold part of IT Tech Packaging's Nov. 19 disclosure. Its newly filed Form 10-K for the year ended Dec. 31, 2025 carries a “Material Uncertainty Related to Going Concern” paragraph from Audit Alliance LLP. Nobody should dress...

Continue Reading
AIM Academy Accreditation Signals a Broader Quality Push

Updated Category News Views 50

Early-childhood education does not hand out many clean, easily comparable scorecards, which is precisely why AIM Academy’s new Cognia recognition deserves a closer look. The Alabama provider has earned Cognia Initial Accreditation, while its Pike Road center received Accreditation with Merit after its Initial Accreditation Review. That is not a revenue event, not a...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Nutritional Solution Developed for Bone Health

Updated Category News Views 162

Advancements in Nutritional Supplements for Bone Health The development of nutritional supplements is an ever-evolving field, and innovative solutions are being crafted to address various health issues. An inventive individual from Montgomery has introduced a product known as BONE SPUR RELIEF, targeting those who endure discomfort from bone spurs, a common condition...

Continue Reading
Historic $115 Million Gift to Launch Conservation School at ASU

Updated Category News Views 341

Historic Donation to Enhance Conservation Education Arizona State University (ASU) has been the fortunate recipient of a remarkable $115 million gift from the Rob Walton Foundation. This donation marks a significant milestone as it represents the largest philanthropic contribution in the university's history and will lead to the formation of the Rob Walton School of...

Continue Reading
Innovative Sports Drink Promises Enhanced Hydration and Focus

Updated Category News Views 501

Introducing a Game-Changing Sports Beverage In today's fast-paced world, individuals are continually on the lookout for healthier alternatives to traditional sports drinks. An exciting new invention known as GATOR-POWER is set to change the landscape of sports beverages. The creator, who hails from Seminole, aspired to design a drink that not only hydrates but also...

Continue Reading
Revelio Labs Strengthens Global Reach Through Salary Board Deal

Updated Category News Views 262

Revelio Labs Expands Its Global Footprint with Strategic Acquisition In an exciting development for workforce analytics, Revelio Labs has made headlines with its latest acquisition of Salary Board. This move is set to significantly enhance Revelio Labs' capabilities in providing comprehensive compensation analytics on a global scale. Integration of Salary Board's Data...

Continue Reading
Global Equity Markets Face Challenges Amidst Volatility

Updated Category News Views 228

Global Equity Performance Amidst Uncertain Times Recent trends in global equity markets indicate a notable decline in trading volumes during the first quarter of the year, reflecting the growing uncertainties that investors face. The ongoing trade tensions between major economies have created an environment where volatility is ever-present, making it difficult for equity...

Continue Reading